Zoetis Inc. (NYSE:ZTS) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 0.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,063,101 shares of the company’s stock after purchasing an additional 515 shares during the quarter. Rhumbline Advisers’ holdings in Zoetis were worth $173,211,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ZTS. AMF Tjanstepension AB boosted its holdings in Zoetis by 23.4% in the third quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock worth $20,594,000 after purchasing an additional 20,001 shares during the period. Exchange Traded Concepts LLC boosted its holdings in shares of Zoetis by 4,582.9% during the third quarter. Exchange Traded Concepts LLC now owns 1,639 shares of the company’s stock valued at $320,000 after acquiring an additional 1,604 shares during the period. Creative Planning boosted its holdings in shares of Zoetis by 8.6% during the third quarter. Creative Planning now owns 90,401 shares of the company’s stock valued at $17,663,000 after acquiring an additional 7,170 shares during the period. Asset Dedication LLC boosted its holdings in shares of Zoetis by 10.4% during the third quarter. Asset Dedication LLC now owns 1,296 shares of the company’s stock valued at $253,000 after acquiring an additional 122 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Zoetis by 18.8% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 8,821 shares of the company’s stock valued at $1,723,000 after acquiring an additional 1,393 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $157.54 on Friday. The company’s 50-day moving average price is $168.89 and its two-hundred day moving average price is $178.98. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock has a market cap of $71.08 billion, a PE ratio of 29.61, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. As a group, sell-side analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis’s payout ratio is presently 37.59%.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ZTS shares. Piper Sandler reduced their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Barclays upped their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday. Morgan Stanley reduced their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. Finally, UBS Group assumed coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $214.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.